Certara, Inc.
Certara, Inc. (NASDAQ: CERT) is a global leader in biosimulation science, technology, and consulting services for model-informed drug development in the biopharmaceutical and biotech industry. The company operates at www.certara.com and provides comprehensive solutions that enable life sciences companies to use data,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Certara, Inc. does
In the company’s own words
Certara, Inc. (NASDAQ: CERT) is a global leader in biosimulation science, technology, and consulting services for model-informed drug development in the biopharmaceutical and biotech industry. The company operates at www.certara.com and provides comprehensive solutions that enable life sciences companies to use data, modeling, and analytics to make better decisions during drug research, development, and commercialization.
The company's core offerings span three integrated areas: biosimulation solutions, scientific informatics, and regulatory science. Certara's biosimulation platforms include the Simcyp Simulator for physiologically based pharmacokinetic modeling and the Phoenix suite for pharmacokinetic and pharmacodynamic analysis. The company's scientific informatics capabilities, expanded through the 2024 acquisition of Chemaxon, support drug discovery workflows including chemical property prediction and compound registration. Regulatory science solutions include CoAuthor software for regulatory document authoring and GlobalSubmit for electronic submission management. Technology-enabled services leverage these platforms to deliver quantitative systems pharmacology, pharmacometrics, clinical pharmacology, and regulatory expertise.
Certara serves more than 2,600 life sciences companies and academic institutions across 70 countries, including 38 of the top 40 biopharmaceutical companies by research and development spending. The company's software products are used by more than 160,000 users and licensed by 20 global drug regulatory agencies, including the FDA, European Medicines Agency, and China's Center for Drug Evaluation. According to internal data, Certara's customers have received 90 percent or more of all novel drug approvals by the FDA from 2014 through 2025.
As of December 31, 2025, Certara employed 1,576 professionals across 28 countries, including 414 employees holding PhD or Doctor of Medicine degrees. The company maintains a portfolio of proprietary intellectual property including 22 issued patents and trademarks such as Simcyp, Phoenix, Pinnacle 21, Vyasa, and Chemaxon. Since 2013, Certara has completed 21 strategic acquisitions to expand its technology capabilities and market reach, positioning itself as an integrated platform provider for model-informed drug development across the entire pharmaceutical development lifecycle.
Company details
- Sector
- Technology
- Industry
- Prepackaged Software
- Headquarters
- RADNOR, PA
- Fiscal year end
- December
- CIK
- 1827090
- SIC
- 7372
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Certara, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Certara, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Certara, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Certara, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Certara, Inc.'s last four quarterly filings that the numbers alone won't show?”